Staphylococcus aureus: Pathogenicity, Antimicrobial Resistance and Clinical Implications.

Adriana Medianeira Rossato, Keli Cristine Reiter, Pedro Alves d’ Azevedo

Resumo


Abstract

 

The pathogenesis of Staphylococcus aureus infections is complex and depends on the host characteristics, expression of virulence factors and ability to develop resistance to antimicrobials. Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most frequent causes of healthcare-associated and community-acquired infections and with its advancement, vancomycin became the main therapeutic option. However, its excessive and inappropriate use has led to the emergence of Staphylococcus aureus with reduced vancomycin susceptibility, as vancomycin-intermediate Staphylococcus aureus (VISA), heterogeneous VISA (hVISA); commonly associated with vancomycin treatment failure, persistent bacteremia, prolonged hospitalization and adverse clinical outcome. This review summarizes the pathogenicity, antimicrobial resistance, and clinical implications of the infections caused by Staphylococcus aureus.

 

Keywords: Staphylococcus aureus; Pathogenicity; Antimicrobial resistance; Reduced susceptibility to vancomycin.


Palavras-chave


Staphylococcus aureus; Patogenicidade; Resistência aos antimicrobianos;

Referências


Casapao AM, Davis SL, McRoberts JP, Lagnf AM, Patel S, Kullar R, et al. Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2014; 58: 4636-41.

Zhang S, Sun X, Chang W, Dai Y, Ma X. Systematic review and meta-analysis of the epidemiology of vancomycin-intermediate and heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. PLoS ONE 2015; 10: e0136082.

Edwards AM, Massey RC, Clarke SR. Molecular mechanisms of Staphylococcus aureus nasopharyngeal colonization. Mol Oral Microbiol 2012; 27: 1-10.

Yamamoto T, Hung WC, Takano T, Nishiyama A. Genetic nature and virulence of community associated methicillin-resistant Staphylococcus aureus. BioMedicine 2013; 3: 2-18.

Tong SYC, Chen LF, Fowler VG. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin Immunopathol 2012; 34: 185-200.

Alfatemi SMH, Motamedifar M, Hadi N, Saraie HSE. Analysis of virulence genes among methicillin-resistant Staphylococcus aureus (MRSA) Strains. Jundishapur J Microbiol 2014; 7: e10741.

Yu F, Liu Y, Lv J, Qi X, Lu C, Ding Y, et al. Antimicrobial susceptibility, virulence determinant carriage and molecular characteristics of Staphylococcus aureus isolates associated with skin and soft tissue infections. Braz J Infect Dis 2015; 19: 614-22.

Gordon CP, Williams P, Chan WC. Attenuating Staphylococcus aureus virulence gene regulation: a medicinal chemistry perspective. J Med Chem 2013, 56: 1389-1404.

Kong C, Neoh H, Nathan S. Targeting Staphylococcus aureus toxins: a potential form of anti-virulence therapy. Toxins 2016; 8: 72.

Avent ML, Vaska VL, Rogers BA, Cheng AC, van Hal SJ, Holmes NE, et al. Vancomycin therapeutics and monitoring: a contemporary approach. Intern Med J 2013; 43: 110-9.

Paterson GK, Morgan FJE, Harrison EM, Cartwright EJP, Torok ME, Zadoks RN, et al. Prevalence and characterization of human mecC methicillin-resistant Staphylococcus aureus isolates in England. Antimicrob Agents Chemother 2014; 69: 907-10.

Gomes DM, Ward KE, Laplante KL. Clinical implications of vancomycin heteroresistant and intermediately susceptible Staphylococcus aureus. Pharmacotherapy 2015; 35: 424-32.

Koh YR, Kim K-H, Chang CL, Yi J. Prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus isolated from hospitalized patients. Ann Lab Med 2016; 36: 235-43.

Hu HC, Kao KC, Chiu LC, Chang CH, Hung CY, Li HF, et al. Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units. BMC Infect Dis 2015; 15: 444.

Costa TM, Morgado PG, Cavalcante FS, Damasco AP, Nouér AS, Santos KRN. Clinical and Microbiological Characteristics of Heteroresistant and Vancomycin-Intermediate Staphylococcus aureus from Bloodstream Infections in a Brazilian Teaching Hospital. PLoS ONE 2016; 11: e0160506.

Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, et al. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant Staphylococcus aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013. J Microbiol Immunol Infect 2015; 1: 1-7.

Koneman EW, Allen SD, Janda WM, Schreckenberger PC, Winn Junior WC. Diagnóstico Microbiológico. 6ª ed. Rio de Janeiro: Editora Guanabara Koogan, 2008. p. 637-43.

Madigan MT, Martinko JM, Dunlap PV, Clarket DP. Microbiologia de Brock. 14ª ed. Porto Alegre: Editora Artmed, 2016. p. 868.

Ingraham JL, Ingraham CA. Introdução a Microbiologia - Uma abordagem em estudos de casos. 3ª ed. São Paulo: Editora Cengage Learning, 2011. p. 527-33.

Sollid JU, Furberg AS, Hanssen AM, Johannessen M. Staphylococcus aureus: determinants of human carriage. Infect Genet Evol 2014; 21: 531-41.

Macal CM, North MJ, Collier N, Dukic VM, Wegeneret DT, et al. Modeling the transmission of community-associated methicillin-resistant Staphylococcus aureus: a dynamic agent-based simulation. J Transl Med 2014;12:1-12.

Khan HA, Ahmad A, Mehboob R. Nosocomial infections and their control strategies. Asian Pac J Trop Biomed 2015; 5: 509–14.

DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010; 375: 1557-68.

Jenkins A, Diep BA, Mai TT, Vo NH, Warrener P, Suzich J, et al. Differential expression and roles of Staphylococcus aureus virulence determinants during colonization and disease. mBio 2015; 6: e02272.

Rodríguez – Noriega E, Seas C. The changing pattern of methicillin-resistant Staphylococcus aureus clones in Latin America: implications for clinical practice in the region. Braz J Infect Dis 2010; 14: S87-S96.

Alvarez C, Labarca J, Salles M. Prevention strategies for methicillin-resistant Staphylococcus aureus (MRSA) in Latin America. Braz J Infect Dis 2010; 14: 107-8.

Smith TC, Forshey BM, Hanson BM, Wardyn SE, Moritz ED. Molecular and epidemiologic predictors of Staphylococcus aureus colonization site in a population with limited nosocomial exposure. Am J Infect Control 2012; 40: 992-6.

Bien J, Sokolova O, Bozko P. Characterization of Virulence Factors of Staphylococcus aureus: Novel Function of Known Virulence Factors That Are Implicated in Activation of Airway Epithelial Proinflammatory Response. J Pathog 2011; 1: 1-13.

Vandenesch F, Lina G, Henry T. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors? Front Cell Infect Microbiol 2012; 2: 12.

Costa AR, Batistão DWF, Ribas RM, Sousa AM, Pereira MO, Botelho CM. Staphylococcus aureus virulence factors and disease. Microbial Pathog 2013; 1: 702-10.

Brown AF, Leech JM, Rogers TR, McLoughlin RM. Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design. Front Immunol 2014; 8: 507-26.

Dayan GH, Mohamed N, Scully IL, Cooper D, Begier E, Eiden J, et al. Staphylococcus aureus: the current state of disease, pathophysiology and strategies for prevention. Expert Rev Vaccines 2016; 15: 1-20.

Waryah CB, Gogoi-Tiwari J, Wells K, Eto KY, Masoumi E, Costantino P, et al. Diversity of Virulence Factors Associated with West Australian Methicillin-Sensitive Staphylococcus aureus Isolates of Human Origin. BioMed Res Int 2016; 2016: 8651918.

Wang B, Muir TW. Regulation of Virulence in Staphylococcus aureus: Molecular Mechanisms and Remaining Puzzles. Cell Chem Biol 2016; 23: 214-24.

Cotar AI, Chifiriuc MC, Holban AM, Banu O. Prevalence of agr specificity groups among Staphylococcus aureus strains isolated from different clinical specimens patients with cardiovascular surgery associated infections. Biointerface Res Appl Chem 212; 2: 264-70.

Gray B, Hall P, Gresham H. Targeting agr- and agr-Like Quorum Sensing Systems for Development of Common Therapeutics to Treat Multiple Gram-Positive Bacterial Infections. Sensors 2013; 13: 5130-66.

Laverty G, Gorman SP, Gilmore BF. Biomolecular mechanisms of staphylococcal biofilm formation. Future Microbiol 2013; 8: 509-24.

Ghasemian A, Peerayeh SN, Bakhshi B, Mirzaee M. Accessory gene regulator specificity groups among Staphylococcus aureus isolated from hospitalized children. Arch Pediatr Infect Dis 2014; 2: e16096.

Quave CL, Horswill AR. Flipping the switch: tools for detecting small molecule inhibitors of staphylococcal virulence. Front Microbiol 2014; 5: 1-10.

Cázares-Domínguez V, Ochoa SA, Cruz-Córdova A, Rodea GE, Escalona G, Olivares AL, et al. Vancomycin modifies the expression of the agr system in multidrug-resistant Staphylococcus aureus clinical isolates. Front Microbiol 2015; 6: 1-12.

Goudarzi M, Goudarzi H, Sá Figueiredo AM, Udo EE, Fazeli M, Asadzadeh M, et al. Molecular Characterization of Methicillin Resistant Staphylococcus aureus Strains Isolated from Intensive Care Units in Iran: ST22-SCCmec IV/t790 Emerges as the Major Clone. PLoS ONE 2016; 11: e0155529.

Rasmussen G, Monecke S, Ehricht R, Söderquist B. Prevalence of Clonal Complexes and Virulence Genes among Commensal and Invasive Staphylococcus aureus Isolates in Sweden. PLoS ONE 2013; 8: e77477.

Lamand V, Dauwalder O, Tristan A, Casalegno JS, Meugnier H, Bes M, et al. Epidemiological data of staphylococcal scalded skin syndrome in France from 1997 to 2007 and microbiological characteristics of Staphylococcus aureus associated strains. Clin Microbiol Infect 2012, 8: E514-21.

Chong YP, Kim ES, Park SJ, Park KH, Kim T, Kim MN, et al. Accessory gene regulator (agr) dysfunction in Staphylococcus aureus bloodstream isolates from South Korean patients. Antimicrob Agents Chemother 2013; 57: 1509-12.

Viedma E, Sanz F, Orellana MA, Juan RS, Aguado JM, Otero JR, et al. Relationship between agr dysfunction and reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus causing bacteremia. J Antimicrob Chemother 2014; 69: 51-8.

Schweizer ML, Furuno JP, Sakoulas G, Johnson JK, Harris AD, Shardell MD, et al. Increased mortality with accessory gene regulator (agr) dysfunction in Staphylococcus aureus among bacteremic patients. Antimicrob Agents Chemother 2011; 55: 1082-7.

Cechinel A, Machado DP, Turra E, Pereira D, Dos Santos RP, Rosa RG, et al. Association between Accessory Gene Regulator Polymorphism and Mortality among Critically III Patients Receiving Vancomycin for Nosocomial MRSA Bacteremia: A Cohort Study. Can J Infect Dis Med Microbiol 2016; 2016: 8163456.

Park M-J, Kim H-S, Kim HS, Kim J-S, Song W, Kim Y, et al. Accessory Gene Regulator Polymorphism and Vancomycin Minimum Inhibitory Concentration in Methicillin-Resistant Staphylococcus aureus Ann Lab Med 2015; 35: 399-403.

Moellering RC. MRSA: the first half century. J Antimicrob Chemother 2012; 67: 4-11.

Stryjewski ME, Corey GR. Methicillin-Resistant Staphylococcus aureus: An Evolving Pathogen. Clin Infect Dis 2014; 58: S10-9.

Chambers HF. Penicillin-binding protein-mediated resistance in pneumococci and staphylococci. J Infect Dis 1999;179: S353-9.

Shore AC, Deasy EC, Slickers P, Brennan G, O'Connell B, Monecke S, et al. Detection of staphylococcal cassette chromosome mec type XI carrying highly divergent mecA, mecI, mecR1, blaZ, and ccr genes in human clinical isolates of clonal complex 130 methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2011; 55: 3765-73.

Otter JA, French GL. Community-associated meticillin-resistant Staphylococcus aureus: the case for a genotypic definition. J Hosp Infect 2012; 81: 143-8.

Stefani S, Chung DR, Lindsay JA, Friedrich AW, Kearns AM, Westh H, et al. Meticillin-resistant Staphylococcus aureus (MRSA): global epidemiology and harmonization of typing methods. Int J Antimicrob Agents 2012; 39: 273-82.

Figueiredo AMS, Ferreira FA. The multifaceted resources and microevolution of the successful human and animal pathogen methicillin-resistant Staphylococcus aureus. Mem Inst Oswaldo Cruz 2014; 109: 265-78.

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. Twenty-Fourth Informational Supplement (M100-S24) 2015; 34: 124-39.

Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J, et al. Combination of Multiplex PCRs for Staphylococcal Cassette Chromosome mec Type Assignment: Rapid Identification System for mec, ccr, and Major Differences in Junkyard Regions. Antimicrob Agents Chemother 2007; 51: 264-74.

Stegger M, Andersen PS, Kearns A, Pichon B, Holmes MA, Edwards G, et al. Rapid detection, differentiation and typing of methicillin‐resistant Staphylococcus aureus harbouring either mecA or the new mecA homologue mecALGA251. Clin Microbiol Infect 2012; 18: 395-400.

International Working Group on the Classification of Staphylococcal Cassete Chromosome Elements (IWG-SCC). Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. Antimicrob Agents Chemother 2009; 53: 4961-7.

Turlej A, Hryniewicz W, Empel J. Staphylococcal cassette chromosome mec (SCCmec) classification and typing methods: an overview. Pol J Microbiol 2011; 60: 95-103.

Ito T, Kuwahara-Arai K, Katayama Y, Uehara Y, Han X, Kondo Y, et al. Staphylococcal cassette chromosome mec (SCCmec) analysis of MRSA. Methicillin-resistant Staphylococcus aureus (MRSA) protocols. Methods Mol Biol 2014; 1085: 131-48.

Li S, Skov RL, Han X, Larsen AR, Larsen J, Sørum M, et al. Novel types of staphylococcal cassette chromosome mec elements identified in clonal complex 398 methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2011; 55: 3046-50.

Hiramatsu K, Ito T, Tsubakishita S, Sasaki T, Takeuchi F, Morimoto Y, et al. Genomic basis for methicillin resistance in Staphylococcus aureus. Infect Chemother 2013; 45: 117–136.

Lawung R, Chuong LV, Cherdtrakulkiat R, Srisarin A, Prachayasittikul V. Revelation of staphylococcal cassette chromosome mec types in methicillin-resistant Staphylococcus aureus isolates from Thailand and Vietnam. J Microbiol Methods 2014; 107: 8-12.

Monecke S, Jatzwauk L, Müller E, Nitschke H, Pfohl K, Slickers P, et al. Diversity of SCCmec Elements in Staphylococcus aureus as Observed in South-Eastern Germany. PLoS ONE 2016; 11: e0162654.

Wu Z, Li F, Liu D, Xue H, Zhao X. Novel type XII staphylococcal cassette chromosome mec harboring a new cassette chromosome recombinase, CcrC2. Antimicrob Agents Chemother 2015; 59: 7597-601.

Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, et al. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int J Antimicrob Agents 2012; 39: 96-104.

Martins A, Riboli DF, Pereira VC, Cunha ML. Molecular characterization of methicillin-resistant Staphylococcus aureus isolated from a Brazilian university hospital. Braz J Infect Dis 2014; 18: 331-5.

Ito T, Katayama Y, Asada K, Mori N, Tsutsumimoto K, Tiensasitorn C, et al. Structural comparison of three types of staphylococcal cassette chromosome mec integrated in the chromosome in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother. 2001; 45: 1323-36.

Ma XX, Ito T, Tiensasitorn C, Jamklang M, Chongtrakool P, Boyle-Vavra S, et al. Novel type of staphylococcal cassette chromosome mec identified in community-acquired methicillin-resistant Staphylococcus aureus strains. Antimicrob Agents Chemother 2002; 46: 1147-52.

Ito T, Ma XX, Takeuchi F, Okuma K, Yuzawa H, Hiramatsu K, et al. Novel type V staphylococcal cassette chromosome mec driven by a novel cassette chromosome recombinase, ccrC. Antimicrob Agents Chemother 2004; 48: 2637-51.

Oliveira DC, Milheiriço C, Lencastre H. Redefining a structural variant of staphylococcal cassette chromosome mec, SCCmec type VI. Antimicrob Agents Chemother 2004; 48: 2637-51.

Berglund C, Ito T, Ikeda M, Ma XX, Söderquist B, Hiramatsu K. Novel type of staphylococcal cassette chromosome mec in a methicillin-resistant Staphylococcus aureus strain isolated in Sweden. Antimicrob. Agents Chemother 2008; 52: 3512-16.

Zhang K, McClure JA, Elsayed S, Conly JM. Novel staphylococcal cassette chromosome mec type, tentatively designated type VIII, harboring class A mec and type 4 ccr gene complexes in a Canadian epidemic strain of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2009; 53: 531-40.

Mccarthy AJ, Lindsay JA. Genetic variation in Staphylococcus aureus surface and immune evasion genes is lineage associated: implications for vaccine design and host-pathogen interactions. BMC Microbiol 2010; 10: 173.

International Working Group on the Classification of Staphylococcal Cassete Chromosome Elements (IWG-SCC). Disponível em: Acesso em: 20 Jun. 2017

Cameron DR, Howden BP, Peleg AY. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis 2011; 53: 576-82.

Sowash MG, Uhlemann A-C. Community-associated methicillin resistant Staphylococcus aureus case studies. Methods Mol Biol 2014; 1085: 25-69.

Otto M. MRSA virulence and spread. Cell Microbiol 2012; 14: 1513-21.

Otto M. Community-associated MRSA: what makes them special? Int J Med Microbiol 2013; 303: 324-30.

Kale P, Dhawan B. The changing face of community-acquired methicillin-resistant Staphylococcus aureus. Indian J Med Microbiol 2016; 34: 275-85.

Chen X, Wang W-K, Han L-Z, Liu Y, Zhang H, Jin Tang J, et al. Epidemiological and genetic diversity of Staphylococcus aureus causing bloodstream infection in Shanghai, 2009-2011. PLoS ONE 2013; 8: e72811.

Pantosti A. Methicillin-resistant Staphylococcus aureus associated with animals and its relevance to human health. Front Microbiol 2012; 3: 1-12.

Smith TC. Livestock-Associated Staphylococcus aureus: The United States Experience. PLOS Pathog 2015; 11: e1004564.

Otter Ja, French GL. Molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus in Europe. Lancet Infect Dis 2010, 10: 227-39.

Rosenthal VD, Maki DG, Mehta Y, Leblebicioglu H, Memish ZA, Al-Mousa HH, et al. International Nosocomial Infection Control Consortium (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module. Am J Infect Control 2014, 42: 942-56.

Sievert DM, et al. Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol 2013, 34: 1-14.

Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2013. Disponível em: Acesso em: 15 Nov. 2016.

Weiner LM, Webb AK, Limbago B, Dudeck MA, Patel J, Kallen AJ, et al. Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011–2014. Infect Control Hosp Epidemiol 2016, 37:1288-1301.

World Health Organization (WHO). Antimicrobial resistance: global report on surveillance. WHO 2014. Disponível em: Acesso em: 15 Nov. 2016.

Centers for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Methicillin-Resistant Staphylococcus aureus, 2014. Disponível em: Acesso em: 15 Nov. 2016.

Levine DP. Vancomycin: a history. Clin Infect Dis 2006; 42: S5-12.

Sakoulas G, Moellering RC. Increasing Antibiotic Resistance among Methicillin-Resistant Staphylococcus aureus Strains. Clin Infect Dis 2008; 46: S360-7.

Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications. Clin Microbiol Rev 2010; 23: 99-139.

Hu Q, Peng H, Rao X. Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus. Front Microbiol 2016; 7: 1-18.

Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-6.

Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997; 350: 1670-3.

Rossi F, Diaz L, Wollam A, Panesso D, Zhou Y, Rincon S, et al. A Transferable Vancomycin Resistance in a Community-Associated MRSA Lineage. N Engl J Med 2014; 370: 1524-31.

Azimian A, Havaei SA, Fazeli H, Naderi M, Ghazvini K, Samiee SM, et al. Genetic Characterization of a Vancomycin-Resistant Staphylococcus aureus Isolate from the Respiratory Tract of a Patient in a University Hospital in Northeastern Iran. J Clin Microbiol 2012; 50: 3581-5.

Melo-Cristino J, Resina C, Manuel V, Lito L, Ramirez M. First case of infection with vancomycin-resistant Staphylococcus aureus in Europe. Lancet 2013; 382: 205.

Limbago BM, Kallen AJ, Zhu W, Eggers P, McDougal LK, Albrecht VS. Report of the 13th Vancomycin-resistant Staphylococcus aureus from the United States. J Clin Microbiol 2014; 52: 998-1002.

Gardete S, Tomasz A. Mechanisms of vancomycin resistance in Staphylococcus aureus. J Clin Invest 2014; 124: 2836-40.

Lin SY, Chen TC, Chen FJ, Chen YH, Lin YI, Siu LK, et al. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center. J Microbiol Immunol Infect 2012; 45: 435-41.

Vas KE, Szász I, Molnár S, Lőrinczi L, Székely. Study of Decreased Susceptibility to Vancomycin in Methicillin-Resistant Staphylococcus aureus Strains isolated from a Romanian Multidisciplinary Emergency Hospital. Roman Rev Labory Med 2014; 22: 245-54.

Di Gregorio S, Perazzi B, Ordoñez AM, De Gregorio S, Foccoli M, Lasala MB, et al. Clinical, microbiological, and genetic characteristics of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia in a teaching hospital. Microb Drug Resist 2015; 21: 25-34.

Silveira AC, Cunha GR, Caierão J, Cordova CM, d'Azevedo PA. Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil. Braz J Infect Dis 2015; 19: 466-72.

Holmes NE, Johnson PDR, Howden BP. Relationship between Vancomycin-Resistant Staphylococcus aureus, Vancomycin-Intermediate Staphylococcus aureus, High Vancomycin MIC, and Outcome in Serious Staphylococcus aureus Infections. J Clin Microbiol 2012; 50: 2548-52.

Devi Y, Punithavathy PM, Thomas S, Veeraraghavan B. Challenges in the Laboratory Diagnosis and Clinical Management of Heteroresistant Vancomycin Staphylococcus aureus (hVISA). Clin Microbiol 2015; 4: 214.

Zhu X, Liu C, Gao S, Lu Y, Chen Z, Sun Z. Vancomycin intermediate-Resistant Staphylococcus aureus (VISA) Isolated from a patient who never received Vancomycin treatment. Int J Infect Dis 2015; 33: 185-90.

Howden BP, McEvoy CR, Allen DL, Chua K, Gao W, Harrison PF, et al. Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR. PLoS Pathog 2011; 7: e1002359.

Wang Y, Li X, Jiang L, Han W, Xie X, Jin Y, et al. Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus. Front Microbiol 2016; 7:2163.

Chen CJ, Lin MH, Shu JC, Lu JJ. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing. J Antimicrob Chemother. 2014; 69: 349-54.

Hiramatsu K, Katayama Y, Matsuo M, Sasaki T, Morimoto Y, Sekiguchi A, et al. Multi-drug-resistant Staphylococcus aureus and future chemotherapy. J Infect Chemother. 2014; 20: 593-601.

Pitz AM, Yu F, Hermsen ED, Rupp ME, Fey PD, Olsen KM. Vancomycin susceptibility trends and prevalence of heterogeneous vancomycin-intermediate Staphylococcus aureus in clinical methicillin resistant Staphylococcus aureus isolates. J Clin Microbiol 2011; 49: 269-74.

Richter SS, Satola SW, Crispell EK, Heilmann KP, Dohrn CL, Riahi F, et al. Detection of Staphylococcus aureus isolates with heterogeneous intermediate-level resistance to vancomycin in the United States. J Clin Microbiol. 2011; 49: 4203-7.

Norazah A, Law NL, Kamel AG, Salbiah N. The presence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in a major Malaysian hospital. Med J Malaysia 2012; 67: 269-73.

Ramli SR, Neoh HM, Aziz MN, Hussin S. Screening and detection of heterogenous vancomycin intermediate Staphylococcus aureus in Hospital Kuala Lumpur Malaysia, using the glycopeptide resistance detection Etest and population analysis profiling. Infect Dis Rep 2012; 4: e20.

Panomket P, Thirat S, Wanram S, Sranujit RP. Methicillin-resistant Staphylococcus aureus with reduced susceptibility to vancomycin in Sanprasitthiprasong Hospital. J Med Assoc Thai 2014; 97: S7-11.

Kirby A, Graham R, Williams NJ, Wootton M, Broughton CM, Alanazi M, et al. Staphylococcus aureus with reduced glycopeptide susceptibility in Liverpool, UK. J Antimicrob Chemother 2010; 65: 721-4.

Adam HJ, Louie L, Watt C, Gravel D, Bryce E, Loeb M, et al. Detection and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates in Canada: results from the Canadian Nosocomial Infection Surveillance Program, 1995–2006. Antimicrob Agents Chemother 2010; 54: 945-9.

Chen H, Liu Y, Sun W, Chen M, Wang H. The incidence of heterogeneous vancomycin-intermediate Staphylococcus aureus correlated with increase of vancomycin MIC. Diagn Microbiol Infect Dis 2011; 71: 301-3.

Liu C, Chen ZJ, Sun Z, Feng X, Zou M, Cao W, et al. Molecular characteristics and virulence factors in methicillin-susceptible, resistant, and heterogeneous vancomycin-intermediate Staphylococcus aureus from central-southern China. J Microbiol Immunol Infect. 2015; 48: 490-6.

Hanaki H, Cui L, Ikeda-Dantsuji Y, Nakae T, Honda J, Yanagihara K, et al. Antibiotic susceptibility survey of blood-borne MRSA isolates in Japan from 2008 through 2011. J Infect Chemother 2014; 20: 527-34

Chaudhary M, Payasi A. Prevalence of heterogeneous glycopeptide intermediate resistance in Methicillin-Resistant Staphylococcus aureus. Am J Infect Dis 2013, 9: 63-70.

Chaudhari CN, Tandel K, Grover N, Sen S, Bhatt P, Sahni AK, et al. Heterogeneous vancomycin intermediate among methicillin resistant Staphylococcus aureus. Med J Armed Forces India. 2015; 71: 15-8.

Silveira AC, Sambrano GE, Paim TG, Caierão J, Cordova CM, d'Azevedo PA. Is prediffusion test an alternative to improve accuracy in screening hVISA strains and to detect susceptibility to glycopeptides/ lipopeptides? Diagn Microbiol Infect Dis. 2014; 79: 401-4.

Sancak B, Yagci S, Gür D, Gülay Z, Ogunc D, Söyletir G, et al. Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey. BMC Infect Dis 2013; 13: 583.

Park KH, Kim ES, Kim HS, Park SJ, Bang KM, Park HJ, et al. Comparison of the clinical features, bacterial genotypes and outcomes of patients with bacteraemia due to heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-susceptible Staphylococcus aureus. J Antimicrob Chemother 2012; 67: 1843-9.

Van Hal SJ, Lodise TP, Paterson DL. Systematic review and meta-analysis of the significance of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates. Antimicrob Agents Chemother 2011; 55: 405-10.

Riederer K, Shemes S, Chase P, Musta A, Mar A, Khatib R. Detection of Intermediately Vancomycin-Susceptible and Heterogeneous Staphylococcus aureus Isolates: Comparison of Etest and Agar Screening Methods. J Clin Microbiol 2011; 49: 2147-50.

Satola SW, Farley MM, Anderson KF, Patel JB. Comparison of detection methods for heteroresistant vancomycin-intermediate Staphylococcus aureus, with the population analysis profile method as the reference method. J Clin Microbiol 2011; 49: 177-83.

Fink SL, Martinello RA, Campbell SM, Murray TS. Low Prevalence of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates among Connecticut Veterans. Antimicrob Agents Chemother 2012; 56: 582-3.

Hu J, Ma XX, Tian Y, Pang L, Cui LZ, Shang H. Reduced Vancomycin Susceptibility Found in Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Clinical Isolates in Northeast China. PLoS One 2013; 8: e73300.

Jacob JT, Diazgranados CA. High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis. Int J Infect Dis 2013; 17: e93-e100.

Kalil AC, Van Schooneveld TC, Fey PD, Rupp ME. Association Between Vancomycin Minimum Inhibitory Concentration and Mortality Among Patients With Staphylococcus aureus Bloodstream Infections. A Systematic Review and Meta-analysis. JAMA 2014; 312: 1552-64.

Van Hal SJ, Lodise TP, Paterson DL. Is It Time to Replace Vancomycin in the Treatment of Methicillin-Resistant Staphylococcus aureus Infections? Clin Infect Dis 2013; 56: 1779-88.

Casapao AM, Leonard SN, Davis SL, Lodise TP, Patel N, Goff DA, et al. Clinical Outcomes in Patients with Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Bloodstream Infection. Antimicrob Agents Chemother 2013; 57: 4252-9.

Van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Antimicrob Agents Chemother 2013; 57: 4252-9.

Yang C-C, Sy C-L, Huang Y-C, Shie S-S, Shu J-C, Hsieh P-H, et al. Risk factors of treatment failure and 30-day mortality in patients with bacteremia due to MRSA with reduced vancomycin susceptibility. Scientific Reports 2018, 8: 7868.

Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother 2011; 17: 52-7.




DOI: https://doi.org/10.26694/repis.v4i0.7625

Apontamentos

  • Não há apontamentos.


Bases/Indexadores:

Internacionais: CuidenIndex Copernicus InternationalResearch BibleLatindexCrossRefScholar Google; REDIB; PKP Index; DOAJ; MIAR

Nacionais: DiadorimIBICTSumarios.orgLIVRE; periodicos CAPES.

REPIS is available in: Publons

ISSN: 2446-7901